A Blinded, Randomized, Multiple-Dose, Parallel Group Study to Characterize the Occurrence of Mild to Moderate Diarrhea After Administration of Neratinib Either 240-mg Once Daily or 120-mg Twice Daily for 14 Days to Healthy Subjects.

Trial Profile

A Blinded, Randomized, Multiple-Dose, Parallel Group Study to Characterize the Occurrence of Mild to Moderate Diarrhea After Administration of Neratinib Either 240-mg Once Daily or 120-mg Twice Daily for 14 Days to Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2012

At a glance

  • Drugs Neratinib (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 01 Jul 2012 Final results published in the Cancer Chemotherapy and Pharmacology.
    • 11 May 2012 Company (Puma Biotechnology) added as reported by ClinicalTrials.gov.
    • 29 Nov 2010 Results presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top